Liquidia (LQDA) Total Current Liabilities (2019 - 2026)
Liquidia's (LQDA) quarterly Total Current Liabilities came in at $149.7 million in Q1 2026, up 147.43% year-on-year from $60.5 million in Q1 2025, and up 10.29% quarter-over-quarter from $135.8 million in Q4 2025.
Liquidia (LQDA) Total Current Liabilities (2019 - 2026) Analysis & Trends
Liquidia's Total Current Liabilities history runs 8 years deep, the most recent figure standing at $149.7 million for Q1 2026.
- On a quarterly basis, Total Current Liabilities rose 147.43% year-over-year to $149.7 million in Q1 2026; TTM through Mar 2026 was $149.7 million, a 147.43% increase from a year earlier, with the FY2025 full-year figure at $135.8 million, up 224.95% from the prior year.
- Total Current Liabilities rose to $149.7 million in Q1 2026 per LQDA's latest filing, from $135.8 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $149.7 million in Q1 2026 and bottomed at $6.8 million in Q1 2023.
- The 5-year median for Total Current Liabilities is $21.9 million (2024), against an average of $43.4 million.
- Across the five-year window, Total Current Liabilities slipped 14.49% in 2023 and soared 224.95% in 2025, its largest moves.
- Year by year, Total Current Liabilities stood at $8.8 million in 2022, then surged by 110.8% to $18.6 million in 2023, then surged by 125.23% to $41.8 million in 2024, then surged by 224.95% to $135.8 million in 2025, then climbed by 10.29% to $149.7 million in 2026.
- Per Business Quant, the three latest LQDA Total Current Liabilities figures stand at $149.7 million (Q1 2026), $135.8 million (Q4 2025), and $102.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 6.56 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.53 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 18.06 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 6.81 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 831.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.66 Bn |
| 10 | Liquidia | 7.84 Bn | 7.61 Bn | 121.79 Mn | 149.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 149.74 Mn |
| Dec 31, 2025 | 135.77 Mn |
| Sep 30, 2025 | 102.94 Mn |
| Jun 30, 2025 | 78.41 Mn |
| Mar 31, 2025 | 60.52 Mn |
| Dec 31, 2024 | 41.78 Mn |
| Sep 30, 2024 | 33.84 Mn |
| Jun 30, 2024 | 24.22 Mn |
| Mar 31, 2024 | 21.93 Mn |
| Dec 31, 2023 | 18.55 Mn |
| Sep 30, 2023 | 12.16 Mn |
| Jun 30, 2023 | 19.50 Mn |
| Mar 31, 2023 | 6.82 Mn |
| Dec 31, 2022 | 8.80 Mn |
| Sep 30, 2022 | 7.46 Mn |
| Jun 30, 2022 | 6.84 Mn |
| Mar 31, 2022 | 7.98 Mn |
| Dec 31, 2021 | 7.33 Mn |
| Sep 30, 2021 | 7.06 Mn |
| Jun 30, 2021 | 6.97 Mn |